title: Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens.
abstract: The development of an effective malaria vaccine remains a global public health priority. Less than 0.5% of the Plasmodium falciparum genome has been assessed as potential vaccine targets and candidate vaccines have been based almost exclusively on single antigens. It is possible that the failure to develop a malaria vaccine despite decades of effort might be attributed to this historic focus. To advance malaria vaccine development, we have fabricated protein microarrays representing 23% of the entire P. falciparum proteome and have probed these arrays with plasma from subjects with sterile protection or no protection after experimental immunization with radiation attenuated P. falciparum sporozoites. A panel of 19 pre-erythrocytic stage antigens was identified as strongly associated with sporozoite-induced protective immunity; 16 of these antigens were novel and 85% have been independently identified in sporozoite and/or liver stage proteomic or transcriptomic data sets. Reactivity to any individual antigen did not correlate with protection but there was a highly significant difference in the cumulative signal intensity between protected and not protected individuals. Functional annotation indicates that most of these signature proteins are involved in cell cycle/DNA processing and protein synthesis. In addition, 21 novel blood-stage specific antigens were identified. Our data provide the first evidence that sterile protective immunity against malaria is directed against a panel of novel P. falciparum antigens rather than one antigen in isolation. These results have important implications for vaccine development, suggesting that an efficacious malaria vaccine should be multivalent and targeted at a select panel of key antigens, many of which have not been previously characterized.
authors.affiliation: Division of Immunology, Queensland Institute of Medical Research, Brisbane, QLD 4006, Australia.
authors.forename: Angela
authors.initials: A
authors.lastname: Trieu
authors.forename: Matthew A
authors.initials: MA
authors.lastname: Kayala
authors.forename: Chad
authors.initials: C
authors.lastname: Burk
authors.forename: Douglas M
authors.initials: DM
authors.lastname: Molina
authors.forename: Daniel A
authors.initials: DA
authors.lastname: Freilich
authors.forename: Thomas L
authors.initials: TL
authors.lastname: Richie
authors.forename: Pierre
authors.initials: P
authors.lastname: Baldi
authors.forename: Philip L
authors.initials: PL
authors.lastname: Felgner
authors.forename: Denise L
authors.initials: DL
authors.lastname: Doolan
mesh_terms: D056704:Adaptive Immunity; D000913:Antibodies, Protozoan / Q000097:blood / Q000235:genetics / Q000276:immunology; D000953:Antigens, Protozoan / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D003001:Cloning, Molecular; D004912:Erythrocytes / Q000469:parasitology; D004926:Escherichia coli; D006801:Humans; D017780:Malaria Vaccines / Q000008:administration & dosage*; D016778:Malaria, Falciparum / Q000097:blood / Q000235:genetics / Q000276:immunology / Q000517:prevention & control*; D013058:Mass Spectrometry; D010957:Plasmids; D010963:Plasmodium falciparum / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D040081:Protein Array Analysis / Q000379:methods*; D040901:Proteomics / Q000379:methods*; D011994:Recombinant Proteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D034101:Sporozoites / Q000276:immunology*; D014169:Transformation, Bacterial; D014611:Vaccination; D014613:Vaccines, Attenuated
chemical_list: D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D017780:Malaria Vaccines; D011994:Recombinant Proteins; D014613:Vaccines, Attenuated